A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors

Eligibility Criteria

• * Measurable disease according to RECIST v1.1
• * Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0 or 1
• * Histologically or cytologically confirmed diagnosis of gastric or gastroesophageal junction adenocarcinoma or breast carcinoma
• * Locally-advanced, unresectable, or metastatic stage
• * Must have experienced disease progression on or after standard of care therapies or be intolerant of standard of care therapies.
• * Histologically or cytologically confirmed diagnosis of breast carcinoma
• * Locally-advanced, unresectable, or metastatic stage
• * HER2-low status determined by most recent local assessment (IHC 1+ or IHC 2+/ISH-negative)
• * Prior therapies requirements
• * No more than 3 prior systemic cytotoxic chemotherapy regimens (including ADCs) for LA/mBC.
• * Participants with known BRCA mutation must have received a PARP-inhibitor where available and not medically contraindicated
• * Have progression on or after, or intolerant to, T-DXd, sacituzumab govitecan, or other topoisomerase I inhibitor therapies, if available as local standard of care therapy
• * Participants with HR+ tumors must have intolerance to endocrine therapy or endocrine therapy refractory disease:
• * Progressed on ≥2 lines of endocrine therapy for LA/mBC AND had received a CDK4/6 inhibitor in the adjuvant or metastatic setting OR
• * Progressed on 1 line of endocrine therapy for LA/mBC AND had a relapse while on adjuvant endocrine therapy after definitive surgery for primary tumor AND had received a CDK4/6 inhibitor in the adjuvant or advanced setting
• * Participants with HR negative, HER2-low and PD-L1-positive (CPS 10 or greater) tumors must have received pembrolizumab with chemotherapy if available as local standard of care therapy.
• * Participants with HR negative, HER2-low and PD-L1-positive (CPS 10 or greater) tumors must have received pembrolizumab (or other PD-(L)1 inhibitor) with chemotherapy if available as local standard of care therapy and not medically contraindicated.
• * Histologically or cytologically confirmed diagnosis breast carcinoma
• * Locally-advanced, unresectable, or metastatic stage
• * HER2+ status determined by most recent local assessment (IHC 3+ or IHC 2+/ISH+)
• * Participants must have:
• * Received prior trastuzumab, pertuzumab and a taxane if available as local standard of care therapy for advanced disease.
• * Have progression on or after, or intolerant to, T-DXd or other topoisomerase I inhibitor therapies
• * No more than 3 prior systemic cytotoxic chemotherapy regimens (including ADCs) for LA/mBC
• * Histologically or cytologically confirmed diagnosis of gastric or gastroesophageal junction adenocarcinoma
• * Locally-advanced, unresectable, or metastatic stage
• * HER2-low expression defined as IHC 1+ or IHC 2+/ISH-negative determined by most recent local assessment
• * Willing and able to provide archival or newly obtained formalin-fixed paraffin-embedded (FFPE) tumor tissue blocks
• * Participants must have received:
• * Prior systemic therapy with platinum, fluorouracil, or taxane for locally advanced unresectable or metastatic disease
• * Progression within 6 months of last dose of (neo)adjuvant cytotoxic chemotherapy is considered as 1 line of systemic therapy for LA/mGC/GEJC
• * Prior anti-PD-(L)1 therapy is allowed
• * No more than 2 prior systemic cytotoxic chemotherapy regimens (including ADC) for LA/mGC/GEJC
• * Must not have received prior treatment with HER2 directed therapy
• * Histologically or cytologically confirmed diagnosis of gastric or gastroesophageal junction adenocarcinoma
• * Locally-advanced, unresectable, or metastatic stage
• * HER2+ status determined by most recent local assessment (IHC 3+ or IHC 2+/ISH+)
• * Participants must have:
• * Received prior trastuzumab plus fluoropyrimidine and platinum containing chemotherapy if no contraindication.
• * Prior T-DXd treatment is allowed
• * Prior PD1 inhibitor therapy is allowed
• * No more than 2 prior systemic cytotoxic chemotherapy regimens (including ADCs) for LA/mGC/GEJC
• * Known hypersensitivity to any excipient contained in the drug formulation of disitamab vedotin or tucatinib
• * Prior therapy with ADCs with MMAE payload
• * Prior therapy with tucatinib
• * Active CNS and/or leptomeningeal metastasis.
• * Participants who have received prior systemic anticancer treatment including investigational agents within 4 weeks prior to first dose of study treatment
• * History of other invasive malignancy within 3 years before the first dose of study intervention, or any evidence of residual disease from a previously diagnosed malignancy.
• * Unable to swallow oral tablets or capsules or any significant GI disease which would preclude the adequate oral absorption of medications